CareDx (NASDAQ:CDNA) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS

CareDx (NASDAQ:CDNA) posted its quarterly earnings data on Tuesday. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.10), Zacks reports. CareDx had a net margin of 17.97% and a return on equity of 18.03%. CareDx updated its FY 2025 guidance to EPS.

CareDx Stock Down 1.7%

Shares of CareDx stock traded down $0.25 on Tuesday, reaching $14.52. The company’s stock had a trading volume of 1,472,937 shares, compared to its average volume of 1,199,126. The company has a market capitalization of $772.86 million, a price-to-earnings ratio of 14.24 and a beta of 2.37. The firm’s fifty day simple moving average is $14.36 and its two-hundred day simple moving average is $15.62. CareDx has a 52 week low of $10.96 and a 52 week high of $26.37.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Craig Hallum reduced their price target on CareDx from $40.00 to $26.00 and set a “buy” rating for the company in a report on Friday, July 18th. Wells Fargo & Company reduced their price objective on shares of CareDx from $19.00 to $14.00 and set an “equal weight” rating for the company in a research note on Friday, August 8th. Wall Street Zen cut shares of CareDx from a “hold” rating to a “sell” rating in a report on Tuesday, October 28th. BTIG Research reaffirmed a “buy” rating and issued a $22.00 target price on shares of CareDx in a report on Tuesday, September 23rd. Finally, Zacks Research cut shares of CareDx from a “hold” rating to a “strong sell” rating in a report on Monday, October 20th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $25.50.

Institutional Trading of CareDx

A number of institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC boosted its stake in shares of CareDx by 120.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock worth $149,000 after buying an additional 4,160 shares during the last quarter. Man Group plc boosted its stake in shares of CareDx by 22.7% in the 2nd quarter. Man Group plc now owns 55,392 shares of the company’s stock worth $1,082,000 after buying an additional 10,252 shares during the last quarter. Meridiem Capital Partners LP purchased a new position in shares of CareDx in the 2nd quarter worth $2,411,000. Lazard Asset Management LLC boosted its stake in shares of CareDx by 642.8% in the 2nd quarter. Lazard Asset Management LLC now owns 102,740 shares of the company’s stock worth $2,006,000 after buying an additional 88,909 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in shares of CareDx in the 2nd quarter worth $821,000.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.